RxDoctor Payments Data

Leanne Camisa, MD

Family Medicine · Placerville, CANPI 1124081377

Payments from drug & device makers

$2,725in general payments, 2019–2025

Across 152 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$562
  • Abbott$440
  • Amgen$312
  • Exact Sciences$183
  • AstraZeneca$174
  • Merck$139
  • plus $914 from 25 others

What the payments were for

  • Food & beverage$2,725100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,725 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$112,750
Medicare patients
500
Services billed
1,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide92$148,787
EliquisApixaban84$109,799
JardianceEmpagliflozin63$87,975
TrulicityDulaglutide34$67,786
JanuviaSitagliptin Phosphate45$52,821
XareltoRivaroxaban19$28,523
MyrbetriqMirabegron23$27,374
Tresiba Flextouch U-200Insulin Degludec11$17,206
LinzessLinaclotide14$16,011
MounjaroTirzepatide11$15,077
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$13,571
BelsomraSuvorexant13$10,451
EntrestoSacubitril/Valsartan11$10,079
Breo ElliptaFluticasone/Vilanterol14$9,170
Testosterone11$6,497

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$49$148,78792 claims
PfizerEliquis, Paxlovid$92$115,454107 claims
Boehringer IngelheimJardiance$96$87,97563 claims
Lilly USA, LLCTrulicity, Mounjaro$57$82,86245 claims
MerckJanuvia, Belsomra$139$63,27258 claims
Johnson & JohnsonXarelto$14$28,52319 claims
Astellas Pharma US IncMyrbetriq$91$27,37423 claims
GSKTrelegy Ellipta, Breo Ellipta$562$22,74129 claims
AbbVieLinzess, Synthroid$32$21,77687 claims
NovartisEntresto$92$10,07911 claims
AstraZenecaSymbicort$174$5,00311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Placerville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →